LONDON (Reuters) – AstraZeneca plans to produce more than 100 million doses of its COVID-19 vaccine – developed by Oxford University – this month, rising to more than £ 200 million a month by April , Chief Pascal Soriot said Thursday.
Mene Pangalos, head of R&D BioPharmaceuticals at British drug retailer, said earlier that the company expects data expected for the U.S. end-of-term trial of its vaccine by the end of March.
Reading out data is “just weeks away”, he said on a media call after the company’s 2020 results were released.
Reciting with Pushkala Aripaka and Ludwig Burger; Written by Josephine Mason; Edited by David Goodman